Tempus AI, Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Tempus AI agreed to acquire Personalis Inc. for $16.25 per share (6% premium to Friday close, 28% premium to 30-day VWAP), representing $1.5B enterprise value net of Tempus' existing stake. The all-stock transaction (with option for up to 50% cash) will close late 2026 or early 2027, subject to Personalis shareholder approval and regulatory clearance. Personalis generated $22.4M Q2 revenue with 10,384 clinical tests (33% QoQ growth); the deal integrates its MRD technology into Tempus' oncology AI platform, targeting a $20B MRD market.
Why this rating
Deal is ~13.6% of Tempus' $11B market cap; strategically meaningful (MRD market, existing partnership), but stock structure and contingencies create execution risk.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.